Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

NCT ID: NCT05030077

Last Updated: 2021-09-01

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 53 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-10-01
• Study Completion Date: 2024-09-01

Brief Summary

Anlotinib is a novel oral multitarget tyrosine kinase inhibitor and primary targeted to VEGFR, FGFR, PDGFR and c-Kit. This study intends to assess the efficacy and safety of anlotinib combined with platinum/gemcitabine for first line treatment of advanced urothelial carcinoma.

Detailed Description

The primary objective is to determine the antitumor activity of anlotinib combined with platinum/gemcitabine (Objective Response rate, ORR) in patients with advanced urothelial carcinoma.

Conditions

Urothelial Carcinoma; Anlotinib; Urogenital Neoplasms; Cisplatin; Carboplatin; Gemcitabine; Antineoplastic Agents

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Anlotinib

Anlotinib(12mg) oral daily for days 1-14, 21 days per cycle

Intervention Type: DRUG

Cisplatin

Cisplatin (70 mg/m2) IV day 1

Intervention Type: DRUG

Carboplatin

If the patients can't tolerate cisplatin, they will be treated with carboplatin (AUC 4.5mg/mL·min) IV day 1

Intervention Type: DRUG

Gemcitabine

Gemcitabine ( 1000 mg/m2) IV days 1 and 8

Intervention Type: DRUG

Other Intervention Names

AL3818

Eligibility Criteria

Inclusion Criteria

1. 18-75 years, ECOG PS: 0-1.

2. Unresectable or metastatic urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis.

3. At least one measurable lesion according to RECIST 1.1.

4. The main organ function meets the following criteria within 7 days before enrollment:

1. Blood tests are subject to the following criteria (without blood transfusion within 14 days): hemoglobin (HB) ≥ 90g / L; neutrophil absolute value (ANC) ≥ 1.5 × 109 / L; platelets (PLT) ≥ 80 × 109 / L.

2. Biochemical tests are subject to the following criteria: total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase AST ≤ 2.5ULN, such as with liver metastasis, then ALT and AST ≤ 5ULN; serum creatinine (Cr) ≤ 1.5ULN or creatinine clearance (CCr) ≥ 60ml / min.

5. Women of childbearing age must have taken reliable contraceptive measures and performed a pregnancy test (serum) within 3 days prior to enrollment, and the results were negative, and were willing to use appropriate methods during the trial and 180 days after the last administration of the test drug.

6. Patients voluntarily joined the study and signed informed consent, with good adherence and follow-up.

Exclusion Criteria

1. Pregnant or lactating women.

2. A history of hypersensitivity to the study drugs.

3. Patients have received systemic treatment.

4. Patients with uncontrolled or high-load central nervous system metastases (or with obvious symptoms)

5. Patients with other diseases, including:

1. Hypertension and uncontrollable levels of normal anti-hypertensive medication: systolic blood pressure≥150 mmHg, diastolic blood pressure≥90 mmHg.

2. Unstable angina, newly diagnosed with angina or acute myocardial infarction within 6 months prior to enrollment, arrhythmia ( including: QTcF of male≥450ms ) requires medical intervention congestive heart failure (New York Heart Association (NYHA)≥2)

3. Active or uncontrollable infections (CTCAE 5.0≥2)

4. Known history of human immunodeficiency virus infection (HIV, congenital immune deficiency disease, or a history of organ transplantation)

5. Urinary protein ≥ ++ or 24 hours urine protein > 1 g

6. Any malignant tumor within 5 years, except those who have been cured or stabilized.

7. Uncured adverse events (NCI-CTCAE 5.0 grade II or greater) due to any treatment before, except for alopecia.

8. There are many factors that affect oral drug absorption (such as inability to swallow, Postgastrointestinal resection, chronic diarrhea and intestinal obstruction, etc.).

9. Abnormal blood coagulation (PT>16s、APTT>43s、TT>21s、Fbg<2g/L), with bleeding tendency or undergoing thrombolysis or anticoagulant therapy. Under the premise of an odds ratio (INR) ≤ 1.5, low-dose heparin (1mg daily) or low-dose aspirin (daily dose ≤ 100 mg) is allowed for preventive purposes.

10. Patients who underwent major surgical treatment, open biopsy, or significant traumatic injury within the first 4 weeks of enrollment.

11. Patients whose tumor has radiographically invaded an important vessel or whose tumor is determined by the investigators to be at high risk of incurring an important vessel and causing fatal hemorrhages during the study period.

12. Patients who have seizures and need treatment.

13. Patients with any signs of hemorrhage or history, regardless of severity; patients with any bleeding or bleeding episodes (NCI-CTCAE 5.0 grade III) within 4 weeks prior to grouping have unhealed wounds, ulcers, or fractures.

14. Artery or venous thrombosis occurred within 6 months, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis, and pulmonary embolism.

15. Patients have been inoculated with attenuated live vaccine within 28 days before enrollment or plan to inoculate vaccine during the trial.

16. Other systemic diseases that can't be controlled (such as diabetes, etc.).

6. Patients with other serious physical or mental illness or laboratory abnormalities that may increase the risk of participating in the study or interfere with the results of the study, as well as patients that the investigator considers unfit to participate in the study.

7. Patients who have participated in clinical trials of other antitumor drugs within four weeks.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tianjin Medical University Second Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yuanjie Niu, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

Tianjin Medical Unversity Second Hospital

Locations

Tianjin Medical Unversity Second Hospital

Tianjin, , China

Countries

China

Central Contacts

Hailong Hu, MD,PhD

Role: CONTACT

Hhllove2004@163.com

0086-13662096232

Yuanjie Niu, MD,PhD

Role: CONTACT

niuyuanjie9317@163.com

0086-13821827881

Facility Contacts

Hailong Hu, MD,PhD

Role: primary

Hhllove2004@163.com

0086-13662096232

Other Identifiers

ALTER-UC-008

Identifier Type: -

Identifier Source: org_study_id